Greywolf Therapeutics’ Post

Last week, Pender & Howe Executive Search partners Celine Chabee and Glenn Lesko attended the 2024 Bloom Burton & Co. Healthcare Investor Conference, a record-breaking event that brought together Canada's leading publicly traded and private healthcare companies. Hosted by Brian Bloom, Jolyon Burton, and the Bloom Burton & Co. team, this conference attracted Canadian, U.S., and international investors interested in the latest developments in Canadian healthcare.   As a stage-agnostic firm specializing in the BioTech, MedTech, and Digital Health industries, Pender & Howe recognizes the transformative impact of strategic human capital on healthcare innovation. We are therefore delighted to acknowledge the exemplary leadership demonstrated by Roberto Bellini, former President and Chief Executive Officer, Bellus Health, Tom Frohlich, former Chief Operating Officer, Chinook Therapeutics, a Novartis Company, and François Ravenelle, former President, and Chief Executive Officer, Inversago Pharma who were honored as 2024 Bloom Burton Award finalists.   Moreover, it was inspiring to see Samira Sakhia, CEO of Knight Therapeutics, showcase the company's impressive growth and celebrate its 10th anniversary! We look forward to Samira sharing Knight Therapeutics' journey at Kestria’s upcoming Global Conference in Montreal.   Further, we would like to highlight a few insights from the Investing in R&D-Stage Healthcare Companies Panel:   1. panelists emphasized the importance of team quality over market type (private or public) as a critical determinant for successful investment; 2. they noted distinct challenges faced by CEOs, particularly contrasting the Canadian market with the American market; 3. additionally, public markets were highlighted as offering more attractive investment opportunities due to the ongoing valuation challenges in private sectors; 4. there was also optimism about the impact of AI on drug discovery, clinical trials, and patient selection, though challenges with validation and the need for better data quality were acknowledged, and 5. finally, there was a strong emphasis on founding a company based on a clear vision rather than being swayed by market conditions.   Lastly, a huge shout-out to TIAP - Toronto Innovation Acceleration Partners, Borden Ladner Gervais LLP (BLG), BIOTECanada, Mintz, and RBCx for hosting lovely events that allowed us to engage in significant discussions and forge meaningful partnerships with our industry peers.   We are eagerly anticipating #BBHIC2025!   #BBHIC2024 #ExecutiveLeadership #InvestorRelations #Entrepreneurship #BusinessGrowth #StrategicPartnerships #HealthcareInvesting #Networking #BusinessDevelopment #Innovation

👨⚕️ Carlsquare x Frontiers Health 💻 On October 17, Carlsquare Managing Partner Caspar Graf Stauffenberg will join CONVEMA Versorgungsmanagement GmbH, an IQVIA business, CEO Dr. Susan Niemeyer on stage at the Frontiers Health conference in Berlin. Come along to learn: 👉 Why a well-prepared exit strategy allows founders to engage with multiple potential buyers and ultimately achieve higher valuations on more favorable terms 👉 Why being exit-ready also preserves founders’ freedom to choose the right path forward, ensuring the company is positioned attractively to different types of acquirers 👉 Practical strategies for maximizing your company’s exit readiness No one knows more than Caspar about exit readiness in the healthcare industry. As CEO he led two life sciences firms through successful exits before moving into M&A, where he has advised on countless additional healthcare transactions. Frontiers Health is one of the premier global health innovation events, with a strong focus on digital therapies, breakthrough technologies, healthcare transformation, investments, and ecosystem development. You can sign up for the conference, enabling you to attend Caspar’s and Susan’s masterclass, using the link below 👇 https://lnkd.in/dNN4MMd #frontiershealth #manda #healthtech #digitalhealth

Want to learn more about MOMA?

Last week, HCAP Partners' Ben C. participated in a panel at the Opus Connect Healthcare Conference in New York. The session, titled CEO Insights on Successful Exits, brought together private equity professionals and CEOs, including Anthony DeSena of HCAP portfolio company PAX Health, to discuss strategies for navigating exit planning in healthcare. Through a detailed case study and interactive Q&A, panelists explored the challenges and triumphs that shape successful outcomes. Thank you to moderator Michael Ritchie and all the panelists for an engaging discussion! #Healthcare #PrivateEquity #ExitPlanning

Next week, our CEO, Dr. Will Briggs, and COO, Dr. Cat Kelly, will be attending the inaugural HLTH Europe event in Amsterdam. HLTH is known for its ability to bring together the health ecosystem, connecting leaders from around the world, including providers, payers, government, pharma, startups, and investors.   Will and Cat will be on the show floor, learning about the latest developments across healthcare, meeting potential partners, and providing insights into the latest innovations from Naitive. 💡 Why meet with us? 🤝 Get insights on how our technology could enhance clinical capabilities in the management of chronic diseases. 🤝 Learn about how opportunistic screening could redefine the care pathways for musculoskeletal health. Are you attending HLTH? Interested in how our approach could improve population health? Let's meet.   #HLTH #PopulationHealth #HealthcareInnovation

Designing a clinical trials is no easy feat. Our CEO Shaherah Yancy is moderating a panel on the basics of designing, developing, and completing your clinical trials at Life Science Tennessee #LSTCON, and it's one of our core offerings at RLS. Click over to our website to learn how we can guide your #startup through your #clinicaltrial - at reasonable rates half that of most CROs.

Reimagining Clinical Trials – A thought-provoking panel moderated by the Managing Principal of Axiom Healthcare Strategies, featuring exertise among physicians and industry leaders: Hossein Borghaei, Corey Langer, Shruti Agrawal, Robert LaCaze, Alan Bash, and Nicholas Davies. Explore innovative approaches transforming traditional trial models. To learn more about our work supporting innovation in study designs, reach out to our Chief of Strategy, Anne Cherry, at ac@axiomhcs.com Watch the full panel here: https://lnkd.in/gbS9MWNY #ClinicalTrials #FutureOfClinicalTrials #InnovatingResearch #ClinicalTrialsReimagined #AxiomSummit

Last month, our team of healthcare investors, Julius Hugelshofer, Stefanos S., and Vittoria Stefanello, had the privilege of attending the Jefferies Healthcare Conference, followed by the European Healthcare Investor Association (E.H.I.A.)'s Annual Gala 2024. The discussions and insights exchanged during both events reaffirmed the dynamic nature of the healthcare sector and its evolving opportunities. 🔑 Key Takeaways from the Jefferies Conference: 🌍 Resilience in Valuation Amidst a Tepid M&A Environment Despite a slower-moving M&A landscape, multiples remain strong. Investment committees are maintaining high standards, prioritizing premium assets. Across Europe, the USA, and Asia, the focus is on value creation, fostering optimism and strengthening investor sentiment. 🏥 A Late 2024 Healthcare Services Pickup? While 2024 has seen slower-than-expected activity in healthcare services, conversations suggest an anticipated pickup in the final quarter. This could set the stage for a robust and busy 2025. 🇪🇺 Awaiting Key Exits in Europe European investors, both buyers and sellers, are closely watching for the first few healthcare service exits following a 24-month pause caused by interest rate hikes and inflationary pressures. When these materialize, they could trigger a snowball effect across the sector. 💡 Creative Approaches to Exits With liquidity challenges, investors are exploring innovative exit strategies, including combinations and continuation funds. At Verlinvest, our evergreen structure positions us well to navigate and capitalize on these trends. 🐾💉 Spotlight on Vets and Aesthetics Interestingly, there’s increasing attention on segments like veterinary care and aesthetics—areas that were often overlooked in healthcare conferences just a few years ago. What trends or opportunities are you seeing in the healthcare space? Let us know in the comments! #Verlinvest #HealthcareInnovation #EHIA2024 #ValueCreation #Investing

Those of you who know me, know that I am a huge advocate of ‘generating the right evidence at the right time to meet stakeholder needs’ to ensure timely access to treatment. I had the privilege of attending both The World Orphan Drug Congress (WODC) and ISPOR EU this year and it was great to see the following themes being shared by the great and the good in our industry: 1. Stakeholder Engagement and early advice, from regulators, payers and don’t forget the patient voice! 2. Strategic Evidence Planning, start early 3. The Growing Role of Real-World Evidence and AI These lessons serve as a powerful reminder of the importance of collaboration, innovation, and strategic planning in healthcare. Here’s to continuing the conversations and partnerships sparked during these events!

Looking forward to participating in this panel discussion on the policy impact on healthcare market access